Risk of COVID-19 disease, dialysis unit attributes, and infection control strategy among London in-center hemodialysis patients

Pan-London COVID-19 Renal Audit Group

doi:10.2215/CJN.03180321

Risk of COVID-19 disease, dialysis unit attributes, and infection control strategy among London in-center hemodialysis patients

Pan-London COVID-19 Renal Audit Group

Research output: Contribution to journal › Article › peer-review

31 Citations (Scopus)

Abstract

Background and objectives Patients receiving in-center hemodialysis treatment face unique challenges during the coronavirus disease 2019 (COVID-19) pandemic, specifically the need to attend for treatment that prevents self-isolation. Dialysis unit attributes and isolation strategies that might reduce dialysis center COVID-19 infection rates have not been previously examined. Design, setting, participants, & measurements We explored the role of variables, including community disease burden, dialysis unit attributes (size and layout), and infection control strategies, on rates of COVID-19 among patients receiving in-center hemodialysis in London, United Kingdom, between March 2, 2020 and May 31, 2020. The two outcomes were defined as (1) a positive test for infection or admission with suspected COVID-19 and (2) admission to the hospital with suspected infection. Associations were examined using a discrete time multilevel time-to-event analysis. Results Data on 5755 patients dialyzing in 51 units were analyzed; 990 (17%) tested positive and 465 (8%) were admitted with suspected COVID-19 between March 2 and May 31, 2020. Outcomes were associated with age, diabetes, local community COVID-19 rates, and dialysis unit size. A greater number of available side rooms and the introduction of mask policies for asymptomatic patients were inversely associated with outcomes. No association was seen with sex, ethnicity, or deprivation indices, nor with any of the different isolation strategies. Conclusions Rates of COVID-19 in the in-center hemodialysis population relate to individual factors, underlying community transmission, unit size, and layout.

Original language	English
Pages (from-to)	1237-1246
Number of pages	10
Journal	Clinical Journal Of The American Society Of Nephrology
Volume	16
Issue number	8
DOIs	https://doi.org/10.2215/CJN.03180321
Publication status	Published - Aug 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2215/CJN.03180321

Cite this

@article{428f565d2ac048bd8545969632edce24,

title = "Risk of COVID-19 disease, dialysis unit attributes, and infection control strategy among London in-center hemodialysis patients",

abstract = "Background and objectives Patients receiving in-center hemodialysis treatment face unique challenges during the coronavirus disease 2019 (COVID-19) pandemic, specifically the need to attend for treatment that prevents self-isolation. Dialysis unit attributes and isolation strategies that might reduce dialysis center COVID-19 infection rates have not been previously examined. Design, setting, participants, & measurements We explored the role of variables, including community disease burden, dialysis unit attributes (size and layout), and infection control strategies, on rates of COVID-19 among patients receiving in-center hemodialysis in London, United Kingdom, between March 2, 2020 and May 31, 2020. The two outcomes were defined as (1) a positive test for infection or admission with suspected COVID-19 and (2) admission to the hospital with suspected infection. Associations were examined using a discrete time multilevel time-to-event analysis. Results Data on 5755 patients dialyzing in 51 units were analyzed; 990 (17%) tested positive and 465 (8%) were admitted with suspected COVID-19 between March 2 and May 31, 2020. Outcomes were associated with age, diabetes, local community COVID-19 rates, and dialysis unit size. A greater number of available side rooms and the introduction of mask policies for asymptomatic patients were inversely associated with outcomes. No association was seen with sex, ethnicity, or deprivation indices, nor with any of the different isolation strategies. Conclusions Rates of COVID-19 in the in-center hemodialysis population relate to individual factors, underlying community transmission, unit size, and layout.",

author = "{Pan-London COVID-19 Renal Audit Group} and Ben Caplin and Damien Ashby and Kieran McCafferty and Richard Hull and Elham Asgari and Ford, {Martin L.} and Nicholas Cole and Marilina Antonelou and Blakey, {Sarah A.} and Vinay Srinivasa and Braide-Azikwe, {Dandisonba C.B.} and Tayeba Roper and Grace Clark and Helen Cronin and Hayes, {Nathan J.} and Bethia Manson and Alexander Sarnowski and Richard Corbett and Kate Bramham and Eirini Lioudaki and Nicola Kumar and Andrew Frankel and David Makanjuola and Sharpe, {Claire C.} and Debasish Banerjee and Salama, {Alan D.}",

note = "Funding Information: M. Antonelou reports receiving research funding from Medical Research Council. D. Ashby reports receiving honoraria from Fibr-ogen. D. Banerjee reports receiving research funding from the British Heart Foundation; receiving grants from AstraZeneca and Kidney Research UK; and receiving honoraria from AstraZeneca, Pfizer, and Viforpharma. S.A. Blakey reports employment with West London Renal and Transplant Centre. K. Bramham reports consultancy agreements with Alexion; receiving honoraria from Alexion and Otsuka; and serving as a scientific advisor or member of Alexion. B. Caplin reports consultancy agreements with LifeArc and receiving research funding from AstraZeneca and grants from Colt Foundation, Medical Research Council, and Royal Free Charity outside the submitted work. R. Corbett has been issued Patent WO2017148836A1: “A device for maintaining vascular connections.” M.L. Ford reports other interests/relationships with the AstraZeneca advisory board, which led to the publication of the paper. A. Frankel reports receiving research funding from Boehringer Ingelheim/Lilly Alliance and receiving honoraria from AstraZeneca, Boehringer Ingelheim/Lilly Alliance, Merck Sharp & Dohme, Napp Pharmaceuticals Limited, and Novo Nordisk. R. Hull reports consultancy agreements with AstraZeneca, Pharmo-cosmos UK Ltd., and Travere Pharmaceuticals; speakers bureau for Napp Phamaceuticals; serving as an elected council member of Renal Association, UK; and other interests/relationships with Joint Specialist Committee Renal Medicine, Royal College Physicians, London. K. McCafferty reports receiving research funding from AstraZeneca and receiving honoraria from Bayer, Napp, Pharma-cosmos, and Vifor Fresenius. A.D. Salama reports receiving research funding from Chiesi and Natera; receiving honoraria from AnaptysBio, AstraZeneca, Hansa Medical, and Vifor Pharmaceuticals; and serving as Nephrology Dialysis Transplantation Editor and a UK Renal Association Executive Member. C.C. Sharpe reports consultancy agreements with Novartis Pharmaceuticals; receiving honoraria from Napp Pharmaceuticals; serving as an Editor for BMC Nephrology and as a trustee and treasurer for the Renal Association; and speakers bureau for Napp Pharmaceuticals. All remaining authors have nothing to disclose. Publisher Copyright: {\textcopyright} 2021 by the American Society of Nephrology. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = aug,

doi = "10.2215/CJN.03180321",

language = "English",

volume = "16",

pages = "1237--1246",

journal = "Clinical Journal Of The American Society Of Nephrology",

issn = "1555-9041",

publisher = "American Society of Nephrology",

number = "8",

}

TY - JOUR

T1 - Risk of COVID-19 disease, dialysis unit attributes, and infection control strategy among London in-center hemodialysis patients

AU - Pan-London COVID-19 Renal Audit Group

AU - Caplin, Ben

AU - Ashby, Damien

AU - McCafferty, Kieran

AU - Hull, Richard

AU - Asgari, Elham

AU - Ford, Martin L.

AU - Cole, Nicholas

AU - Antonelou, Marilina

AU - Blakey, Sarah A.

AU - Srinivasa, Vinay

AU - Braide-Azikwe, Dandisonba C.B.

AU - Roper, Tayeba

AU - Clark, Grace

AU - Cronin, Helen

AU - Hayes, Nathan J.

AU - Manson, Bethia

AU - Sarnowski, Alexander

AU - Corbett, Richard

AU - Bramham, Kate

AU - Lioudaki, Eirini

AU - Kumar, Nicola

AU - Frankel, Andrew

AU - Makanjuola, David

AU - Sharpe, Claire C.

AU - Banerjee, Debasish

AU - Salama, Alan D.

N1 - Funding Information: M. Antonelou reports receiving research funding from Medical Research Council. D. Ashby reports receiving honoraria from Fibr-ogen. D. Banerjee reports receiving research funding from the British Heart Foundation; receiving grants from AstraZeneca and Kidney Research UK; and receiving honoraria from AstraZeneca, Pfizer, and Viforpharma. S.A. Blakey reports employment with West London Renal and Transplant Centre. K. Bramham reports consultancy agreements with Alexion; receiving honoraria from Alexion and Otsuka; and serving as a scientific advisor or member of Alexion. B. Caplin reports consultancy agreements with LifeArc and receiving research funding from AstraZeneca and grants from Colt Foundation, Medical Research Council, and Royal Free Charity outside the submitted work. R. Corbett has been issued Patent WO2017148836A1: “A device for maintaining vascular connections.” M.L. Ford reports other interests/relationships with the AstraZeneca advisory board, which led to the publication of the paper. A. Frankel reports receiving research funding from Boehringer Ingelheim/Lilly Alliance and receiving honoraria from AstraZeneca, Boehringer Ingelheim/Lilly Alliance, Merck Sharp & Dohme, Napp Pharmaceuticals Limited, and Novo Nordisk. R. Hull reports consultancy agreements with AstraZeneca, Pharmo-cosmos UK Ltd., and Travere Pharmaceuticals; speakers bureau for Napp Phamaceuticals; serving as an elected council member of Renal Association, UK; and other interests/relationships with Joint Specialist Committee Renal Medicine, Royal College Physicians, London. K. McCafferty reports receiving research funding from AstraZeneca and receiving honoraria from Bayer, Napp, Pharma-cosmos, and Vifor Fresenius. A.D. Salama reports receiving research funding from Chiesi and Natera; receiving honoraria from AnaptysBio, AstraZeneca, Hansa Medical, and Vifor Pharmaceuticals; and serving as Nephrology Dialysis Transplantation Editor and a UK Renal Association Executive Member. C.C. Sharpe reports consultancy agreements with Novartis Pharmaceuticals; receiving honoraria from Napp Pharmaceuticals; serving as an Editor for BMC Nephrology and as a trustee and treasurer for the Renal Association; and speakers bureau for Napp Pharmaceuticals. All remaining authors have nothing to disclose. Publisher Copyright: © 2021 by the American Society of Nephrology. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/8

Y1 - 2021/8

N2 - Background and objectives Patients receiving in-center hemodialysis treatment face unique challenges during the coronavirus disease 2019 (COVID-19) pandemic, specifically the need to attend for treatment that prevents self-isolation. Dialysis unit attributes and isolation strategies that might reduce dialysis center COVID-19 infection rates have not been previously examined. Design, setting, participants, & measurements We explored the role of variables, including community disease burden, dialysis unit attributes (size and layout), and infection control strategies, on rates of COVID-19 among patients receiving in-center hemodialysis in London, United Kingdom, between March 2, 2020 and May 31, 2020. The two outcomes were defined as (1) a positive test for infection or admission with suspected COVID-19 and (2) admission to the hospital with suspected infection. Associations were examined using a discrete time multilevel time-to-event analysis. Results Data on 5755 patients dialyzing in 51 units were analyzed; 990 (17%) tested positive and 465 (8%) were admitted with suspected COVID-19 between March 2 and May 31, 2020. Outcomes were associated with age, diabetes, local community COVID-19 rates, and dialysis unit size. A greater number of available side rooms and the introduction of mask policies for asymptomatic patients were inversely associated with outcomes. No association was seen with sex, ethnicity, or deprivation indices, nor with any of the different isolation strategies. Conclusions Rates of COVID-19 in the in-center hemodialysis population relate to individual factors, underlying community transmission, unit size, and layout.

AB - Background and objectives Patients receiving in-center hemodialysis treatment face unique challenges during the coronavirus disease 2019 (COVID-19) pandemic, specifically the need to attend for treatment that prevents self-isolation. Dialysis unit attributes and isolation strategies that might reduce dialysis center COVID-19 infection rates have not been previously examined. Design, setting, participants, & measurements We explored the role of variables, including community disease burden, dialysis unit attributes (size and layout), and infection control strategies, on rates of COVID-19 among patients receiving in-center hemodialysis in London, United Kingdom, between March 2, 2020 and May 31, 2020. The two outcomes were defined as (1) a positive test for infection or admission with suspected COVID-19 and (2) admission to the hospital with suspected infection. Associations were examined using a discrete time multilevel time-to-event analysis. Results Data on 5755 patients dialyzing in 51 units were analyzed; 990 (17%) tested positive and 465 (8%) were admitted with suspected COVID-19 between March 2 and May 31, 2020. Outcomes were associated with age, diabetes, local community COVID-19 rates, and dialysis unit size. A greater number of available side rooms and the introduction of mask policies for asymptomatic patients were inversely associated with outcomes. No association was seen with sex, ethnicity, or deprivation indices, nor with any of the different isolation strategies. Conclusions Rates of COVID-19 in the in-center hemodialysis population relate to individual factors, underlying community transmission, unit size, and layout.

UR - http://www.scopus.com/inward/record.url?scp=85112277968&partnerID=8YFLogxK

U2 - 10.2215/CJN.03180321

DO - 10.2215/CJN.03180321

M3 - Article

C2 - 34074636

AN - SCOPUS:85112277968

SN - 1555-9041

VL - 16

SP - 1237

EP - 1246

JO - Clinical Journal Of The American Society Of Nephrology

JF - Clinical Journal Of The American Society Of Nephrology

IS - 8

ER -

Risk of COVID-19 disease, dialysis unit attributes, and infection control strategy among London in-center hemodialysis patients

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this